Infectious Disease

Excessive titer convalescent plasma with decrease threat of demise from COVID-19

January 14, 2021

1 min read

Source / information

Disclosure:
Joyner reports on connections with the Biomedical Advanced Research and Development Authority, Mayo Clinic, Schwab Charitable Fund, United Health Group, National Basketball Association, and Millennium Pharmaceuticals Octapharma USA, Inc., as well as grants from the National Heart, Lunch and Blood Institute during the study. In the study you will find all relevant financial information from all other authors.

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

Among hospital patients with COVID-19 who were not mechanically ventilated, receiving high-titer convalescent plasma was associated with a lower risk of death than receiving plasma with lower antibody levels, researchers reported.

“In response to the coronavirus pandemic, the Mayo Clinic, with the support and guidance of the Research and Development Agency for Biomedical Advances and the FDA, initiated the US Convalescent Plasma Access Program to access and assess the safety profile this experiment to enable therapy, “ Michael YY Joyner, MD, an anesthetist at the Mayo Clinic, explained Healio.

Michael YY Joyner

Joyner and colleagues conducted a retrospective study using the expanded access program registry to determine anti-SARS-CoV-2 immunoglobulin G antibody levels in convalescent plasma used to treat hospitalized adults with COVID-19. They rated patients who had measured anti-SARS-CoV-2 antibody levels and 30-day mortality data available by July 4. According to the study, the primary outcome was death within 30 days of the plasma transfusion.

Of the 3,082 patients included in their analysis, 115 of 515 patients (22.3%) were in the high titer group, 549 of 2,006 patients (27.4%) were in the medium titer group and 166 of 561 patients (29, 6%) in the low titer group Joyer and colleagues reported that the titer group died within 30 days of the plasma transfusion.

They observed a lower risk of death within 30 days in the high-titer group compared to the low-titer group in patients who had not received mechanical ventilation before the transfusion (RR = 0.66; 95% CI, 0.48-0 , 91), but no effect in patients who received mechanical ventilation (RR = 1.02; 95% CI, 0.78-1.32)

“Transfusing plasma with higher levels of anti-SARS-CoV-2 IgG antibodies was associated with lower mortality than transfusing plasma with lower antibody levels,” said Joyner. “Patients who received plasma within 3 days of diagnosis had a lower mortality rate than patients who were transfused later in the disease.”

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

COVID-19 Resource Center

COVID-19 Resource Center

Related Articles